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The mainstay treatment of pulmonary disorders lies around the direct drug targeting to the lungs 2 
using a nebulizer, metered-dose inhaler, or dry powder inhaler. Only few inhalers are available 3 
in the market that could be used for inhalational drug delivery in rodents. However, the 4 
available rodent inhalers invariably require high cost and maintenance, which limits their use 5 
at laboratory scale. The present work, therefore, was undertaken to develop a simple, reliable 6 
and cost-effective nose-only inhalation chamber with holding capacity of three mice at a time. 7 
The nebulized air passes directly and continuously from the central chamber to mouthpiece and 8 
maintains an aerosol cloud for rodents to inhale. Laser diffraction analysis indicated volume 9 
mean diameter of 4.02 ± 0.30 µm and the next-generation impactor studies, however, revealed 10 
mean mass aerodynamic diameter of 3.40 ± 0.27 μm, respectively. An amount of 2.05 ± 0.20 11 
mg of voriconazole (VRC) was available for inhalation at each delivery port of the inhaler. In 12 
vivo studies indicated the deposition of 76.12 ± 19.50 µg of VRC in the mice lungs when 13 
nebulized for a period of 20 minutes. Overall, the developed nose-only inhalation chamber 14 
offers a reliable means of generating aerosols and successfully exposing mice to nebulization. 15 
KEYWORDS: Nebulizer, Aerosols, Voriconazole, Preclinical, Spraytec. 16 
INTRODUCTION 17 
Inhalational drug delivery has been gaining immense importance in the treatment of various 18 
respiratory disorders for the last two decades. It offers distinct advantages of rapid onset of 19 
action, thin epithelial barrier, reduced dosage amount, localized action, avoidance of first-pass 20 
effect and gastrointestinal (GI) problems (1-3). A wide range of inhalational devices like 21 
nebulizers, dry powder inhalers (DPIs) and metered dose inhalers (MDIs) are available in the 22 
market to deliver drug molecules effectively to the human lungs (4-6). However, the availability 23 
of inhalation devices for carrying out the preclinical testing in rodents of drug therapeutics or 24 
their novel formulations at laboratory scale is quite limited.  25 
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Majorly, two types of inhalation exposure chambers, viz., whole-body exposure and head/nose-26 
only exposure have been employed in the preclinical testing of inhalational drug products (7-27 
9). Other direct instillation methods, like intratracheal instillation or dry powder insufflation, 28 
have also been used by the researchers to introduce the drug therapeutics directly to the lungs 29 
(10, 11). Nevertheless, these commercially available rodent inhalers are too costly to meet up 30 
the standard laboratory requirements, particularly for scientists working in developing 31 
countries. To overcome such issues, some of the researchers have built their in-house inhalers 32 
in order to conduct preclinical testing in rodents (12-15).  The initial in-house models reported 33 
in the literature consisted of glass bottles, where the rodents were placed either inside the bottles 34 
(16) or in a side-exit of the bottle for inhalation (17). Tests were also conducted using inhalation 35 
boxes, where cotton pieces or filter disks moistened with test material were placed and fixed 36 
inside the box for inhalation by the rodents (18, 19). Some researchers have also used square-37 
shaped or cylindrical inhalation chambers, connected with nebulizers, for the generation of an 38 
aerosol cloud for inhalation (20, 21).  39 
Development and validation of a nose-only inhalation chamber for mice was reported by Kaur 40 
et al. (2008) for delivering microparticles (MPs) of rifabutin in the form of dry powder (10). 41 
Out of the 20 mg of fluidized MPs, about 2.5 mg were collected at the delivery port in 30 s of 42 
operation, but only 61.5 µg of drug was inhaled by the mice. Albeit the design of the inhaler 43 
was quite simple and easy to fabricate, yet it suffered from serious limitations of inconsistency 44 
(being manually operated) and time-consumingness (being applicable for one animal at one 45 
time). Subsequently, Yi et al. (2013) fabricated and validated a whole-body exposure chamber 46 
to study the toxicity profile of titanium oxide nanoparticles (NPs) in rodents (22). The inhalation 47 
chamber consisted of an aerosol generator, exposure chamber and a monitoring system. The 48 
aerosols, generated from dry powder containing NPs were delivered to the exposure chamber 49 
at a flow rate of 90 liters per minute. Despite the attainment of controlled and uniform aerosol 50 
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atmosphere of NPs during the whole process of inhalation exposure, several drawbacks were 51 
associated with this type of inhalation chamber. These encompassed the use of a large amount 52 
of formulation or drug being tested, aerosol exposure to other parts of rodent like skin or fur, 53 
and acute requirement of excellent mixing for attaining uniform distribution of aerosol within 54 
the chamber (1, 23). Sinha et al. (2013) also developed a nose-only inhalation chamber for dry 55 
powder insufflation and nebulization taking six rodents at one time (13). The inhalation 56 
chamber was made up of centrifuge tubes and a polypropylene-rectangular box, employing 57 
voriconazole (VRC; in solution and micronized form) as a model drug.   In vivo drug deposition 58 
was found to be significantly higher in case of DPI (i.e., 80–130 μg/g) vis-à-vis the nebulizer 59 
(i.e., 40-68 μg/g). The developed inhaler, however, had limitations of large inhalation chamber 60 
and inability to keep the holding chambers at equidistant levels from the inlet (i.e., DPI or 61 
nebulizer), resulting eventually in uneven distribution of the inhalable dose. Recently, Silva et 62 
al. (2017) developed and evaluated a round-wall glass inhalation chamber for preclinical testing 63 
in rodents connected to a nebulizer on the upper side and animal holders the lower side (24). 64 
Activation of the nebulizer passed air directly from the central portion to the holding chambers, 65 
while the vapors within the chamber were collected and analyzed using gas chromatography. 66 
Significant loss, however was noticeable, ostensibly owing its large central chamber (~8 cm 67 
area), thus limiting its usage for the aerosolization of expensive drugs. Besides inhalation of 68 
drugs, nose-only inhalation chambers have also been reported for the rodents for nebulizing 69 
chronic wasting disease prions,  infective bioaerosols and aqueous solutions of radiolabelled 70 
human serum albumin formulation (12, 25, 26). Various pitfalls associated with these inhalation 71 
chambers included complex and costly design set-up and difficulty to emulate the same at 72 
laboratory levels. 73 
The present research work, thus accordingly was undertaken to develop a simple, efficient, 74 
reliable, reproducible and low-cost nose-only inhalation exposure system with an aim to 75 
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minimize the aerosol loss in the central chamber and to meet up the standard requirements of 76 
preclinical testing at the small-scale laboratory. The developed inhalation chamber was 77 
evaluated and validated using in vitro and in vivo tests both, employing VRC as the model drug.  78 
MATERIALS AND METHODS  79 
Instrument and Reagents 80 
The jet nebulizer was procured from Philips, New Delhi, India. Centrifuge tubes (50 mL) were 81 
purchased from Tarsons, New Delhi, India. VRC was generously supplied as a gift sample by 82 
M/s Panacea Biotech, New Delhi, India. The HPLC-grade solvents, viz., acetonitrile (ACN) 83 
and methanol, were purchased from M/s Fisher, New Delhi, India. All other chemicals used 84 
were of high purity or analytical grade and were employed as such obtained. 85 
Design of Inhalation Chamber  86 
Based on the know-how gained from the previous inhaler reports, the nose-only inhalation 87 
chamber was designed using readily available objects. The low-cost inhalation chamber 88 
consisted of five major parts, a) nebulizer as aerosol generator; b) a three-way splitter as central 89 
chamber; c) flexible tubing as a linker, i.e., connect nebulizer to three-way splitter; d) a small 90 
rectangular vial (5.5 cm length, 3 cm diameter) as mouthpiece for rodents and e) centrifuge 91 
tubes (50 mL) as mice holding chambers or restrainers. 92 
Analytical and Bioanalytical Method Development 93 
Analysis of VRC was performed as per the analytical method developed and validated in our 94 
laboratory using a mobile phase consisting of ACN and acetic acid solution (50:50), at a flow 95 
rate of 1 mL/min. The entire analysis was conducted employing a reversed-phase C18 column, 96 
250 x 4.6 (mm) with a particle size of 5 µm (Purospher® STAR, Merck) and a PDA detector 97 
using a wavelength of 256 nm under isocratic conditions. 98 
A standard stock solution of VRC (10 mg/mL) was prepared in methanol: water (1:1), which 99 
was further diluted to obtain a drug concentration of 100 µg/mL. Various working standard 100 
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solutions i.e., 0.1-50 µg/mL were serially prepared from the stock solution (100 µg/mL). For 101 
bioanalytical estimation, an aliquot of 200 μL of lung homogenate was added to 200 μL of 102 
working standard solutions with volume make up to 1 mL using ACN. The mixture blend was 103 
vortexed, centrifuged and filtered through a 0.22 μm syringe filter prior to subjecting for HPLC 104 
analysis.  105 
Determination of Microdroplet Size of an Aerosol 106 
The microdroplet size of an aerosol was measured using the Spraytec laser diffraction 107 
instrument (Malvern Instruments, UK), equipped with a He-Ne laser. A lens with a focal length 108 
of 300 mm was used covering microdroplet size between 0.1 and 900 µm. Briefly, 5 mL of the 109 
sample was loaded on to the jet nebulizer and placed perpendicularly to the laser lens line of 110 
the instrument at a distance of 3 cm from the laser beam (27). The values of volume mean 111 
diameter (VMD), geometric standard deviation (GSD) and the fine particle fraction (FPF) were 112 
computed using the Spraytec version 3.20 software after passing aerosol droplets through the 113 
laser beam (28). 114 
Determination of Pulmonary Deposition by Next-Generation Impactor 115 
Pulmonary deposition studies were performed using a Next-Generation Impactor (NGI) at a 116 
flow rate of 15 L/minute (29). The nebulizer was connected to the induction port of NGI 117 
(COPLEY Scientific, UK) with a mouthpiece adapter, filled with 5 mL of inhalation solution 118 
with an aerosol collection time of 5 minutes. Once the measurement was completed, the cup 119 
holder tray was removed and each of its stages was washed with 10 mL of extraction solvent 120 
(i.e., methanol), filtered and subjected to HPLC analysis for determining the VRC content at 121 
each stage of the impactor. The mass median aerodynamic diameter (MMAD) and geometric 122 
standard deviation (GSD) were calculated using online MMAD calculation software (30). 123 
Emitted dose (ED), i.e., the total amount of drug emitted from the inhaler device and fine 124 
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particle fraction (FPF), i.e., the ratio of the mass of particles less than 5 µm to the emitted dose, 125 
was also calculated (31).  126 
Determination of Nebulized Air-Flow at Each Delivery Port 127 
The nebulized airflow reaching each delivery port was determined with the help of a gas flow 128 
meter MGF 505 (Metrex, New Delhi, India). The flow meter was attached to one of the three 129 
outlets of the central chamber, with the rest of the two outlets closed with the help of a glass 130 
stopper. The airflow value of all the three delivery ports was determined in order to confirm the 131 
uniformity of airflow during operation (24). 132 
Determination of Dose Available for Inhalation 133 
The initial characterization of the exposure chamber was performed using pre-weighed cotton 134 
balls (250.12 ± 13.09 mg), placed close to the delivery port of the holding chambers (10). 135 
Different concentrations of VRC (1-3 mg/mL) in a solution of normal saline were nebulized for 136 
a period of 20 minutes. During operation, the surface of the cotton ball was exposed to the 137 
aerosol generated from the nebulizer. After corresponding periodic time-intervals, the nebulizer 138 
was turned-off, the balls were removed using forceps from the tube and were weighed on a 139 
precision analytical balance (Mettler Toledo ME204, Ohio, USA). Furthermore, VRC was 140 
estimated quantitatively employing an HPLC-based analytical technique after soaking the 141 
cotton ball in a solvent blend of methanol and water (1:1) for 2 h, followed by bath sonication 142 
for 10 minutes and filtration using 0.22 µm filters. Once the amount of the VRC at each delivery 143 
port was confirmed, the performance of the developed inhalation chamber was further tested in 144 
the animals studied. 145 
Validation of Inhaled Voriconazole in Balb/c Mice 146 
The animal experiments were carried out after obtaining the requisite ethical approval from the 147 
Institutional Animal Ethics Committee of Panjab University, Chandigarh, India 148 
(PU/45/99/CPSEA/IAEC/2019/243). Balb/c mice weighing 23 ± 2 g, were procured and 149 
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provided with a standard diet and water ad libitum. Prior to each experiment, mice were fasted 150 
for 12 h with free access to water. Animals received nebulization of 3 mg/mL of VRC (Vorier, 151 
Aspiro Pharma, Telangana, India) for a period of 20 minutes. During the experiment, the test 152 
solution was aerosolized using a jet nebulizer, i.e., Philips Respironics InnoSpire compressor 153 
nebulizer with a volume capacity of 15 mL. Ten milliliters of VRC solution in normal saline (3 154 
mg/mL) was placed into the nebulizer fluid cup, mice were loaded into the apparatus and the 155 
entire chamber was placed in a secondary enclosure in a well-vented room. The aerosol 156 
generated by the nebulizer entered the central chamber and reached the delivery port. Each 157 
animal was positioned in such a way that the nose of the mice was exposed to the delivery port. 158 
The air exhaled by the animal escaped from the mouthpiece via a small opening present at the 159 
upper wall near the apex. As the central chamber and mouthpiece were airtight, no air entered 160 
or left the exposure system except via the aerosol delivery and exhaust. At specified time 161 
intervals of 0.5, 2 and 6 h, animals (n=3) were sacrificed by cervical dislocation, the lungs were 162 
removed, homogenized in PBS 7.4 (5 mL) for 5 minutes employing a tissue homogenizer 163 
(Heidolph, RZR 2011, Germany) and stored at -20ºC until analyzed. At the time of experiment, 164 
the samples were thawed and 200 µL of lung homogenate was added to 1 mL of ACN followed 165 
by vortexing for 20 minutes. The samples were centrifuged for 10 minutes at 10,000 rpm (9055 166 
× g) and the supernatant was then filtered through 0.22 μm syringe filters prior to HPLC 167 
analysis. The percent drug deposition in lungs in vivo was measured by dividing the total VRC 168 
deposited in the lung tissue with the amount of drug available for inhalation at the delivery 169 
ports, obtained during the in vitro studies. 170 
Statistical Analysis 171 
Values were listed as means ± SD. Statistical comparison of means was performed by unpaired 172 
Students t-test and one-way ANOVA. Statistical analysis was performed using GraphPad 173 
Prism, Version 4.03.  174 
9 
 
RESULTS AND DISCUSSIONS 175 
Design of Inhalation Chamber 176 
The development of a low-cost nose-only inhalation chamber started with a review of various 177 
inhaler devices reported in the literature to date (12, 14, 25, 26, 33-35). After analyzing the data, 178 
a final sketch of the model equipment was prepared with an aim to minimize the aerosol loss in 179 
the central chamber (i.e., connect nebulizer to animal restrainer), preferably using readily 180 
available, inexpensive, easy to disassemble and clean objects. 181 
In order to design the apparatus for use by three animals at a time and to minimize the drug 182 
wastage, a three-way splitter (Fig. 1) of diameter 1 cm, approximately 8-fold less than the 183 
recently developed inhaler (24), was used as the central chamber. The trifurcations of the central 184 
chamber were placed at the equidistant levels from the inlet to ensure uniformity in the dose 185 
delivered to each mouthpiece and ultimately to the delivery ports of the animal restrainers. 186 
Moreover, the small size of the central chamber reduced the time required for its saturation, 187 
thus economizing both time as well as drug amount. A small rectangular vial was used as a 188 
mouthpiece that was connected to each outlet of the central chamber. A small hole or vent was 189 
also made in the wall of each mouthpiece, near the rim of the screw cap, in order to minimize 190 




Fig. 1. A three-way splitter as central chamber depicting the flow pattern of the aerosol. 193 
Centrifuge tubes with a diameter of 1.8 cm were used as the mouse-holding chambers or 194 
restrainers, as these are routinely used in the laboratories and are small enough to prevent any 195 
plausible change in the direction of movement by the animals. Moreover, their cylindrical 196 
structure with a narrow front and large aperture at the distal part allowed easier introduction 197 
and removal of an animal weighing 23 ± 2 g. The tips of the centrifuge tubes were removed to 198 
make a hole of around 0.9 cm diameter, so that nose of the mouse can easily be inserted into 199 
these. Care was exercised to leave a smooth edge to avoid any discomfort to the animal. The 200 
holding chambers were designed in such a way that mainly the nose of the mouse was exposed 201 
to the aerosol cloud, as shown in the photograph (Fig. 2). The animals were restrained with the 202 




Fig. 2. Aerosol-exposure to mice in the holding chamber. 205 
A flexible tubing, with 25 cm length and 1.2 cm diameter, was employed to connect the mouth 206 
of the nebulizer with the central portion of the three-way splitter. It serves the purpose of 207 
transferring the mist generated from the nebulizer to the delivery port through the central 208 
chamber. The fabrication of the inhalation chamber is depicted in the photograph (Fig. 3). The 209 
compressor attached to the nebulizer provides a positive pressure of 12.1 ± 1.2 psi for the 210 
generation of an aerosol mist. After the final assemblage, the inhalation chamber was checked 211 
for any leakage by nebulizing it with distilled water. Any leaks detected were sorted and fixed 212 




Fig. 3. Design of the inhalation chamber coupled with a nebulizer. 215 
Analytical and Bioanalytical Method Development 216 
Linear calibration curves were generated with working standards for the quantification of VRC 217 
in cotton balls and in the lungs. Validation of linearity range was carried out by constructing 218 
the residuals plots (inset), which indicated the percent deviation in responses, well within ± 5% 219 
limit of the working VRC concentrations as illustrated in Fig. 4 (A, B). A chromatogram 220 
showing the peak of VRC in methanol: water and in lung homogenate is illustrated in Fig. 5 221 





Fig. 4: Calibration plot of VRC in A) methanol: water and B) lung homogenates. The inset 225 






Fig. 5. The chromatogram of voriconazole in (A) methanol: water (B) lung homogenates. 230 
Determination of Microdroplet Size of Aerosol 231 
Fig. 6 represents the frequency and cumulative volume distribution profile of the aerosol 232 
generated through a jet nebulizer. Laser diffraction analysis yielded a VMD of 4.02 ± 0.30 µm 233 
and GSD of 1.79 ± 0.02 µm. The proportion of microdroplets with a diameter below 5 µm, i.e., 234 
the fine-particle fraction (FPF), was found to be 62.62 ± 0.45 %. Thus, VMD of less than 5µm 235 








Fig. 6: Particle size distribution of voriconazole microdroplets. 242 
Particle Deposition Studies by Next-Generation Impactor 243 
Fig. 7 illustrates the deposition of VRC at various stages of the impactor, indicating maximum 244 
drug deposition on Stage 3 (i.e., cutoff of 5.4 μm), Stage 4 (i.e., cutoff of 3.3 μm) and Stage 5 245 
(i.e., cutoff of 2.08 μm) of the impactor. The MMAD and GSD were found to be 3.40 ± 0.27 246 
μm and 2.14 ± 0.10 μm, respectively, with 49.30 ± 3.66 % of dose emitted from the nebulizer 247 
and 40.00 ± 2.47 % of FPF. The observed MMAD was found to be less 4 µm, construing that 248 
the nebulization of model drug exhibits targeting potential in the airways, primarily by the 249 
mechanism of sedimentation and diffusion (1, 36). In this context, a GSD of >1.2 known to 250 
indicate a heterodisperse aerosol size distribution, in accordance with the results generally 251 




Fig. 7: In vitro pulmonary deposition studies on percentage of voriconazole deposition using a 254 
next generation impactor at 15 L min-1. Each crossbar indicates 1 SD. 255 
Determination of Air-flow at each Delivery Port 256 
The airflow observed at each delivery port was found to be quite consistent, i.e., close to 4.21 257 
± 0.13 L/min at each outlet, when the other two outlets were closed. This could be attributed to 258 
the uniformity maintained by the three-way splitter in delivering the aerosolized drug to each 259 
delivery port of the animal holding chamber. Further, the air reaching at all the delivery ports 260 
could be analyzed by dividing the above value by number of delivery ports (i.e., 3) which is 261 
1.40 ± 0.13 L/min at each delivery port. 262 
In vitro Optimisation 263 
Before the start of the experiment, the nebulizer was primed for 1 minute to saturate the central 264 
chamber and to maintain a steady flow to the delivery port. The in vitro test conducted with 265 
cotton balls revealed the enhancement in the weight of cotton balls by small increments of 5.42 266 
± 0.18 mg. A total of 10 mL solution was nebulized initially, out of which 5.17 ± 0.25 mL was 267 
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remaining after nebulization of 20 minutes. An amount of 2.05 ± 0.20 mg (14.5 %) of VRC was 268 
recovered at the highest concentration tested (3 mg/mL) at each of the delivery ports with a 269 
coefficient of variation less than 18%.  In total, 6.12 ± 0.60 mg drug (43.4%) was available at 270 
all of the delivery ports with 14.10 ± 0.15 mg of total drug nebulized and 15.90 ± 0.75 mg of 271 
total amount corresponds to dead dose in the nebulizer. The dose recovered has been 10-folds 272 
and 1.2-folds higher than the previously reported articles (10, 14). Fig. 8 presents the VRC 273 
fraction obtained across each delivery port, connected to a central chamber through the 274 
mouthpiece. As observed, the fraction of VRC recovered increases in the holding chambers, as 275 
the concentration approaches towards maximum. Moreover, it was noted that the relative mass 276 
fraction did not vary substantially among the three-exposure ports at each of the concentration 277 
tested (p>0.05), evidently owing to the equidistant position of all the holding chambers with 278 
respect to the central chamber. 279 
 280 
Fig. 8: Optimisation of dose available at each of the delivery ports at varied concentrations of 281 




Validation of Inhaled Voriconazole in Balb/c Mice 284 
Fig. 9 illustrates the biodistribution profile of VRC in the lungs following inhalation using a 285 
nebulizer. An amount of 76.12 ± 19.50 µg (3.81 ± 0.97 %) of VRC was deposited in the whole 286 
lungs following nebulization for 20 minutes (Table 1), followed by a declining trend up to 6 h. 287 
This could be attributed to the fast rate of drug diffusion of the previously solubilized VRC 288 
molecule, large alveolar surface area and thin physiological membrane in the lungs. Therefore, 289 
the results substantiate the successful application of the developed inhaler device in the 290 
nebulization of VRC microdroplets in mice lungs. 291 
 292 
                      Fig. 9:  Lung distribution profile of voriconazole in mice lungs after nebulization for 293 














The present study demonstrates the development of a simple, cheap and efficient nose-only 306 
inhalational chamber for routine analysis of the aerosols, generated through nebulization for 307 
use in rodents (20-25 g). Reliability of the inhalation chamber was validated, attributable to the 308 
uniform distribution (p > 0.05) of the test particles across the three-delivery ports. Moreover, 309 
reduction in the area of the central chamber reduces drug wastage, thus economizing the cost 310 
for highly expensive drugs like VRC and anticancer drugs. Further, the apparatus could prove 311 
to be a promising tool for preclinical testing of drugs per se or their novel formulations, 312 
administered through nebulization at the laboratory scale. Moreover, the device can also be 313 
opted for short-or long-term toxicological investigations in rodents. The benefits of the device 314 
can also be subsequently extended for usage in larger rodents (around 250g) by just switching 315 
over to animal restrainers. 316 
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